Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

ERR2208943

—

a94510e1-49de-59a6-bbff-a4273f057c80

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.600
  • COAGULATION+0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • MYOGENESIS+0.500
  • TGF_BETA_SIGNALING+0.400
  • APICAL_JUNCTION+0.300
  • COMPLEMENT+0.300
  • HEDGEHOG_SIGNALING+0.300
  • KRAS_SIGNALING_UP+0.300
  • PANCREAS_BETA_CELLS+0.300

Top 10 suppressed

  • E2F_TARGETS-0.500
  • G2M_CHECKPOINT-0.500
  • MYC_TARGETS_V2-0.500
  • INTERFERON_ALPHA_RESPONSE-0.400
  • MYC_TARGETS_V1-0.400
  • INTERFERON_GAMMA_RESPONSE-0.300
  • UNFOLDED_PROTEIN_RESPONSE-0.300
  • ALLOGRAFT_REJECTION-0.200
  • MITOTIC_SPINDLE-0.200
  • MTORC1_SIGNALING-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CQ-6227-01A-11R-1915-07
head-neck@1
——0.893
23d97737f-01a1-43f1-ba35-ee7cc84dc7ff
colon-landscapes@1
——0.887
3SRR8518203
breast-umap@18
—A0.875
4TCGA-BH-A0BP-01A-11R-A115-07
breast-umap@18
—A0.870
5TCGA-GM-A2DK-01A-21R-A180-07
breast-umap@18
—B0.860
687a582d2-22f0-4d22-8d2d-8fec2f1e7e8f
melanoma-umap@29
——0.859
7MBCproject_0031_T1_RNA
breast-umap@18
—A0.844
8TCGA-CN-6019-01A-11R-1686-07
head-neck@1
——0.837
9TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.832
10SRR8613790
breast-umap@18
—A0.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.600Remibrutinib— uncovered
COAGULATION0.500Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
MYOGENESIS0.500Inavolisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
XENOBIOTIC_METABOLISM0.300Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
HEME_METABOLISM0.100Temsirolimus— uncovered